Skip to content

Study · Non-randomized trial · n = 8 · 1994

9 results

Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas.

Colombo P, Ambrosi B, Saccomanno K, Bassetti M, Cortelazzi D, Faglia G

European journal of endocrinology1 Apr 1994Cited by 7 (Europe PMC)

PMID8162161 (opens in a new tab)DOI10.1530/eje.0.1300339 (opens in a new tab)PepBankPUB-08162161
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with non-functioning pituitary adenomas, hormonal responses to acute GnRH were generally blunted during nafarelin treatment versus pretreatment.

    In plain wordsIn patients with non-functioning pituitary adenomas, hormone responses to GnRH were generally lower during nafarelin treatment than before treatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseHormonal responses to GnRH
    Study

    n = 8

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Hormonal responses to an acute GnRH test during nafarelin administration were generally blunted when compared to the pretreatment responses.
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with non-functioning pituitary adenomas, visual fields did not change during nafarelin treatment.

    In plain wordsIn patients with non-functioning pituitary adenomas, visual fields did not change during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeVisual field
    Study

    n = 8

    Comparator
    Pretreatment
    Outcome group
    Vision and retina · Eye
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    No changes of visual field and tumor size occurred in any patient during treatment.
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with non-functioning pituitary adenomas, tumor size did not change during nafarelin treatment.

    In plain wordsIn patients with non-functioning pituitary adenomas, tumor size did not change during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeTumor size
    Study

    n = 8

    Comparator
    Pretreatment
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    No changes of visual field and tumor size occurred in any patient during treatment.
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  4. 04HumanNon-randomized trialSafety outcome

    One patient with a non-functioning pituitary adenoma developed left palpebral ptosis after 12 months of nafarelin and underwent repeat surgery.

    In plain wordsOne patient with a non-functioning pituitary adenoma developed a drooping left eyelid after 12 months of nafarelin and required repeat surgery.

    Peptide
    Nafarelin
    Outcome
    Not applicablePalpebral ptosis requiring surgery
    Study

    n = 8

    Outcome group
    Adverse events · Eye
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Measurements

    Patients with left palpebral ptosis
    1 patient
    after 12 months of therapy; had a second transsphenoidal surgery

    Source sentences

    Summary
    However, one patient who showed a persistent increase in FSH levels exhibited left palpebral ptosis after 12 months of therapy and underwent a second transsphenoidal surgery.(ABSTRACT TRUNCATED AT 250 WORDS)
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  5. 05HumanNon-randomized trialEfficacy outcome

    In four patients with non-functioning pituitary adenomas, nafarelin significantly lowered LH from pretreatment levels.

    In plain wordsIn four patients with non-functioning pituitary adenomas, nafarelin significantly lowered LH from pretreatment levels.

    Peptide
    Nafarelin
    Outcome
    DecreaseLH suppression
    Study

    n = 4

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In four patients (nos. 1,2,3,5) nafarelin significantly lowered luteinizing hormone (LH) levels, and also follicle-stimulating hormone (FSH) in three of them (nos. 1,2,3).
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  6. 06HumanNon-randomized trialEfficacy outcome

    In three patients with non-functioning pituitary adenomas, nafarelin significantly lowered FSH from pretreatment levels.

    In plain wordsIn three patients with non-functioning pituitary adenomas, nafarelin significantly lowered FSH from pretreatment levels.

    Peptide
    Nafarelin
    Outcome
    DecreaseFSH suppression
    Study

    n = 3

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In four patients (nos. 1,2,3,5) nafarelin significantly lowered luteinizing hormone (LH) levels, and also follicle-stimulating hormone (FSH) in three of them (nos. 1,2,3).
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  7. 07HumanNon-randomized trialEfficacy outcome

    In three patients with non-functioning pituitary adenomas, persistent FSH stimulation occurred during nafarelin treatment.

    In plain wordsIn three patients with non-functioning pituitary adenomas, FSH remained stimulated during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    IncreasePersistent FSH stimulation
    Study

    n = 3

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Persistent FSH stimulation occurred in three patients (nos. 6,7,8), with a transient slight LH increase only in patient no. 8.
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  8. 08HumanNon-randomized trialEfficacy outcome

    In one patient with a non-functioning pituitary adenoma, LH increased slightly and transiently during nafarelin treatment.

    In plain wordsIn one patient with a non-functioning pituitary adenoma, LH increased slightly and temporarily during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    IncreaseTransient LH increase
    Study

    n = 1

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Persistent FSH stimulation occurred in three patients (nos. 6,7,8), with a transient slight LH increase only in patient no. 8.
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.
  9. 09HumanNon-randomized trialEfficacy outcome

    In one patient with a non-functioning pituitary adenoma, nafarelin treatment persistently stimulated alpha-subunit levels.

    In plain wordsIn one patient with a non-functioning pituitary adenoma, alpha-subunit levels remained stimulated during nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    IncreaseAlpha-subunit stimulation
    Study

    n = 1

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1200 micrograms/day or 800 micrograms/day for 3 months followed by 1200 micrograms/day · intranasal · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In one patient (no. 7), alpha SU levels were persistently stimulated.
    3 context sentences
    Summary · context
    The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal.
    Summary · context
    Nafarelin was administered intranasally for 1 year to all patients.
    Summary · context
    Four patients received a dose of 1200 micrograms/day; the remaining four received 800 micrograms/day for 3 months, which was subsequently increased to 1200 micrograms/day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.